# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-26-001116
**Filing Date:** 2026-2
**Character Count:** 11109
**Document Hash:** df1f4c15e7088b529e656a5eb6dd8da3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-001116.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0001654954-26-001116

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260211

**FILED AS OF DATE**: 20260211

**DATE AS OF CHANGE**: 20260211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 26619296

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

 **UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2026

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

 **GSK plc (the 'Company**')

Transaction notification

---

| | | | |
|:---|:---|:---|:---|
| **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| a) | Name<br>| Luke Miels | Luke Miels |
| b) | Position/status<br>| Chief Executive Officer | Chief Executive Officer |
| c) | Initial notification/amendment<br>| Initial notification | Initial notification |
| **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| a) | Name | GSK plc | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Luke Miels will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares. | Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Luke Miels will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares. |
| c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| c) | Price(s) and volume(s) | £21.68<br>| 24979.493 |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| d) | Aggregated volume<br> Price<br>|  |  |
| e) | Date of the transaction<br>| 2026-02-10 | 2026-02-10 |
| f) | Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| a) | Name<br>| Regis Simard | Regis Simard |
| b) | Position/status<br>| President, Global Supply Chain | President, Global Supply Chain |
| c) | Initial notification/amendment<br>| Initial notification | Initial notification |
| **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| a) | Name<br>| GSK plc | GSK plc |
| b) | LEI<br>| 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Regis Simard will receive a cash payment of £270,777.70 less applicable tax withholding in respect of 12,489.746 notional Ordinary Shares. | Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Regis Simard will receive a cash payment of £270,777.70 less applicable tax withholding in respect of 12,489.746 notional Ordinary Shares. |
| c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| c) | Price(s) and volume(s) | £21.68<br>| 12489.746 |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| d) | Aggregated volume<br> Price<br>|  |  |
| e) | Date of the transaction<br>| 2026-02-10 | 2026-02-10 |
| f) | Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| a) | Name<br>| Deborah Waterhouse | Deborah Waterhouse |
| b) | Position/status<br>| CEO, ViiV Healthcare and President, Global Health, GSK | CEO, ViiV Healthcare and President, Global Health, GSK |
| c) | Initial notification/amendment<br>| Initial notification | Initial notification |
| **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| a) | Name<br>| GSK plc | GSK plc |
| b) | LEI<br>| 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br> ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Deborah Waterhouse will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares. | Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Deborah Waterhouse will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares. |
| c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| c) | Price(s) and volume(s) | £21.68<br>| 24979.493 |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| d) | Aggregated volume<br> Price<br>|  |  |
| e) | Date of the transaction<br>| 2026-02-10 | 2026-02-10 |
| f) | Place of the transaction<br>| N/A | N/A |

---

 **About GSK**

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <u>www.gsk.com</u>.

 **Registered in England & Wales:**

No. 3888792

 **Registered Office:**

79 New Oxford Street

London

WC1A 1DG

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: February 11, 2026 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---